The global nephrology and urology devices market size was valued at USD 5.24 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030. The high incidence of chronic kidney diseases (CKDs), coupled with the rising elderly population, is a high-impact rendering driver for the market. According to the estimates of the National Kidney Foundation, 10.0% of the worldwide population is affected by chronic kidney diseases. The increasing patient population pool is seeking the treatment of this disorder, thereby boosting the overall demand for nephrology and urology devices.
The COVID-19 is expected to have a short-term and moderate impact on industry growth. The impact of the outbreak on the market varies per country, depending on the local state of health systems and the actions taken to combat the pandemic. Urological surgeries were considered non-urgent during the pandemic. Due to this, all outpatient, as well as elective interventional procedures, were reduced or interrupted for reducing the risk. Specialty centers for dialysis and related services were also shut down during this period, which further negatively impacted the industry growth. Moreover, the industry participants witnessed a significant decline in sales generated during 2020. For instance, in 2020, Olympus Corporation witnessed sales of USD 6,652.4 million and observed a decrease of 3.3% compared to 2019. This was due to the decreased sales from ureteral access sheath, cystoscopes, ancillary products, and ureteroscopes.
However, as lockdown restrictions are being lifted in most countries, the supply chains of most healthcare companies are expected to work effectively and smoothly over the forecast period. Thus, the global market is expected to grow at a significant rate in the coming years. For instance, between the fourth quarter of 2020 and the first quarter of 2021, most elective surgeries were resumed as the regulations imposed by the governments in various countries were relaxed. This has increased the patient volume in hospitals and dialysis centers, which has partially regularized the sales of nephrology and urology devices worldwide. To cite an example, Boston Scientific Corporation's 2021 revenue was USD 11,888 million, an increase of 19.9% compared to 2020 revenue. The sales were primarily driven by the resumed urological treatments and surgeries globally. Moreover, the COVID-19 outbreak has created opportunities for local manufacturers. These firms are adopting various plans and policies to gain a greater market share. Players are partnering with relevant third-party vendors to reinforce their foothold in the market.
The rising incidence of diabetes and high blood pressure (hypertension) globally is also contributing to the growth of this industry as these two diseases are the primary reasons for kidney failure. As per the data published by the American Kidney Fund, 38.4% of kidney failures are because by diabetes and 25% of kidney failures are a result of high blood pressure. This high correlation between kidney failure and the aforementioned disorders is expected to accentuate the growth of the overall market. Moreover, the number of people with diabetes and hypertension is increasing in developing countries of the APAC and MENA regions owing to changes in lifestyle and the geriatric population. For instance, as per the International Diabetes Federation, in 2019, 55 million adults are living with diabetes in the IDF Middle East and North Africa (MENA) Region, which is estimated to reach 108 million by 2045. These factors are expected to increase the demand for and use of nephrology and urology devices in medical settings during the forecast period.
In addition, the market is expected to be driven by a large geriatric population, which is highly susceptible to various diseases including kidney and urinary disorders. As per the WHO, the global population of 65 years and above is expected to rise from 7% in 2000 to 16% in 2050. Old age is considered one of the greatest risk factors for developing various medical conditions. Aging also weakens the immune system and consequently increases a patient’s susceptibility to various ailments such as renal disorders, diabetes, prostate cancer, and urinary retention. According to the American Society of Nephrology, urologic diseases are the third most common concern among the geriatric population, and these account for approximately around 47% of physician visits. Thus, the increasing geriatric population is one of the significant drivers for the market over the forecast period.
Furthermore, the growing demand for minimally invasive procedures due to the recent technological innovations is expected to increase the sale of nephrology and urology devices in the market. The nephrology and urology devices, such as ureteral stents, catheters, guidewires, and renal dilators, are developed using advanced materials, such as nitinol, polyurethanes/polycarbonates, and silicone. Carbothane is a material resistant to several chemicals, such as iodine, hydrogen peroxide, or alcohol, which increases its life. For instance, the Mahurkar Chronic Carbothane catheter, developed by Medtronic is made of Carbothane, which provides superior kink resistance and facilitates simple single insertion while facilitating high flow rates with low arterial and vein pressure. Thus, the usage of advanced materials during manufacturing will offer several advantages like enhanced strength and resistance, thereby increasing demand for the devices and fueling industry growth.
Countries such as the U.S. and Canada have witnessed a high prevalence rate of chronic kidney and urinary disorders owing to sedentary lifestyles. In addition, the increasing number of patients undergoing surgeries and rising consumer awareness regarding minimally invasive surgeries are contributing to the industry growth in these countries. In addition, as per the Population Reference Bureau fact sheet, the number of people in the U.S. aged 65 and above is expected to nearly double from 52 million in 2018 to 95 million by 2060 (a rise from 16% to 23%). Consequently, the growth of the geriatric population is expected to expand the patient pool for the manufacturers of nephrology and urology devices. Similarly, according to the Canadian Institute for Health Information’s (CIHI) report Canadian Organ Replacement Register (CORR), 2019, Manitoba, a Canadian Province, the number of people in Manitoba on dialysis has increased by 57% from 2009 to 2019.
Moreover, due to the recent COVID-19 outbreak, healthcare facilities such as hospitals have been exhausted by a large influx of such patients; therefore, many countries have postponed elective surgeries and other healthcare procedures for an indefinite period. Additionally, the demand for renal disease treatment products used in home settings has increased as patients suffering from chronic kidney diseases are seeking home treatment options and/or outpatient clinics. Similarly, the demand for home healthcare among the aging population is increasing as it is at a higher risk of acquiring the infection and cannot visit any healthcare facility. Home health service providers are offering multiple home care services, including delivery of medicines and purchase, or rent of dialysis-related equipment. This is likely to increase the industry growth during the forecast period.
Furthermore, the presence of a large number of hospitals in the U.S., coupled with a well-developed healthcare infrastructure, is another factor contributing to industry growth. For instance, according to the American Hospital Association, there were 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. A significant increase in the number of hospitals and hospital admissions for acute kidney injuries (AKIs) is boosting the demand for dialysis and transplant, thereby propelling industry growth. Moreover, with the rising prevalence of CKD, the number of dialysis clinics and treatment centers is growing. For instance, as of 2020, there were around 7,500 dialysis clinics in the U.S. This factor is expected to positively impact industry growth.
The others segment held the largest revenue share of over 25.0% in 2021 owing to the high prevalence of prostate and colorectal cancer, AKIs, and urolithiasis and the launch of technologically advanced products by the key players. For instance, according to the National Health Service (NHS) England, around 61.0% of the male population are suffering from lower urinary tract infections and over 34.0% of women are living with some type of urinary incontinence. Moreover, the increasing prevalence of the diseases such as hypertension and diabetes indicates a higher chance of people suffering from kidney diseases as both these diseases are the major risk factors for kidney diseases. Thus, the increasing prevalence of such diseases is expected to boost segment growth. Based on product, the market has been segmented into ureteral catheters, Percutaneous Nephrostomy (PCN) catheters, urinary stents, stone baskets, urology guidewires, renal dilators, and others.
The PCN catheters segment is expected to expand at the highest CAGR of 7.8% from 2022 to 2030 owing to its numerous applications in urological disorders such as treatment of renal transplant complications, decompression of the perinephric or nephric fluid collection, and nondilated obstructive therapy. Thus, the increasing prevalence of urological diseases, such as cervical cancer, and the benefits offered by the PCN catheters are expected to drive the market. For instance, as per the Human Papillomavirus (HPV) Centre fact sheet 2018, in Saudi Arabia, every year, around 316 women are diagnosed with cervical cancer and 158 women die due to this disease. This is expected to boost the segment growth during the forecast period.
North America held the largest revenue share of over 30.0% in 2021 owing to an increase in the prevalence of kidney-associated disorders, rising government initiatives regarding treatment, highly skilled physicians, and the presence of well-established healthcare facilities. Furthermore, increasing research funding for the development of advanced devices is positively influencing the industry growth in this region. Additionally, the rising prevalence of diabetes and hypertension increases the risk of developing urology and nephrology diseases, which is expected to further increase the demand for nephrology and urology devices in this region. For instance, according to the U.S. Department of Health and Human Services in 2021, about 37 million people, or more than 1 in 7 U.S. adults may have chronic kidney disease (CKD), which is expected to drive the market in North America.
The Asia Pacific is expected to witness significant growth from 2022 to 2030 owing to various factors such as rising awareness related to kidney and urinary disorders, increasing healthcare expenditure levels, and improving healthcare facilities in this region. The increasing prevalence of Benign Prostatic Hyperplasia (BPH), spinal cord injury, and Urinary Tract Infection (UTI) is driving the market in the Asia Pacific. UTI is one of the most prevalent infectious diseases in this region. Additionally, the urgent need for the development of new systems and replacing and upgrading existing medical infrastructure are other factors contributing to the growing demand for these devices.
The Middle East and Africa are estimated to closely follow Asia Pacific in terms of CAGR. The African-Middle East ethnicity has been observed to be the most prone to CKD among global populations. The incidence rate of CKD among African-Middle Eastern countries stands at 18-23% of the total population, which is significantly higher than the global population. Socio-economic factors such as income and access to modern facilities have led to extensive changes in the lifestyle of people, thus leading to lifestyle-related diseases such as obesity, cancer, and heart disease. For instance, as per the International Diabetes Federation, 55 million adults were living with diabetes in the International Diabetes Federation Middle East and North Africa (IDF MENA) region in 2019, and it is estimated to increase to 108 million by 2045.
Companies are constantly launching new products and increasing their reach by geographically expanding to gain a greater market share. For instance, Terumo Corporation (a Japan-based company) acquired Sequent Medical (a U.S.-based medical device manufacturer) through its subsidiary in the U.S. Thus, the global players are shifting their production facilities to other countries to achieve economies of scale.
Moreover, numerous manufacturers in the nephrology and urology devices industry work in partnership with key medical device distributors to market and supply their products globally or in certain countries. Therefore, strategic alliances are quite common among them. Such alliances not only help the manufacturers acquire the license to market their products, but also reduce their liability in case of product recall and adverse events. For instance, in February 2019, Coloplast signed a three-year agreement with Premier Inc., a U.S.-based healthcare improvement company, for its urology products. The general urological products include drainage systems, catheters, and other accessories, thereby increasing penetration of the product in a new market. Some prominent players in the global nephrology and urology devices market include:
Hollister Incorporated
Medtronic
Coloplast
Boston Scientific Corporation
ConvaTec Group
B. Braun AG
Teleflex Inc.
Baxter
Fresenius Medical Care
Asahi Kasei Corp.
Cook Group
C. R. Bard Inc.
Terumo Corporation
Nxstage Medical Inc.
Nipro Corporation
Report Attribute |
Details |
Market size value in 2022 |
USD 5.57 billion |
Revenue forecast in 2030 |
USD 9.44 billion |
Growth rate |
CAGR of 6.8% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; Colombia; Argentina; South Africa; Saudi Arabia; UAE |
Medtronic; Coloplast; Boston Scientific Corporation; ConvaTec Group; B. Braun AG; Hollister; Teleflex Inc.; Baxter; Fresenius Medical Care; Asahi Kasei Corp.; Cook Group; C. R. Bard Inc.; Terumo Corporation; Nxstage Medical Inc.; Nipro Corporation |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global nephrology and urology devices market report based on product, application, end-user, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Ureteral Catheters
PCN Catheters
Urinary Stents
Stone Basket
Urology Guidewires
Renal Dilators
Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
Urolithiasis
Urological Cancer & BPH
Bladder Disorders
Kidney Diseases
Others
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global nephrology and urology devices market size was estimated at USD 5.24 billion in 2021 and is expected to reach USD 5.57 billion in 2022.
b. The global nephrology and urology devices market is expected to grow at a compound annual growth rate of 6.8% from 2022 to 2030 to reach USD 9.44 billion by 2028.
b. North America dominated the nephrology & urology devices market with a share of 33.06% in 2021. This is attributable to the presence of prominent players, advanced healthcare infrastructure, high disposable income, and patients’ willingness and ability to pay.
b. Some of the key players operating in the nephrology & urology devices market include Medtronic, Coloplast, Boston Scientific Corporation, ConvaTec Group PLC, B. Braun Melsungen AG, Hollister Incorporated, Teleflex Incorporated, and J and M Urinary Catheters LLC.
b. Key factors that are driving the nephrology and urology devices market growth include increasing incidence of nephrology and urology disorders, the growing use of the technologically advanced materials in the device’s development and an increasing number of minimally invasive procedures.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.